BRAINLIFE.ORG





Topics


Glioblastoma | Treatment | Targeted therapy | Navtemadlin






Home > Publications > Topics > Glioblastoma > Treatment > Targeted therapy > Navtemadlin






Rendo V, Lee EQ, Bossi C, Khuu N, Rudek MA, Pal S, Reynolds ARN, Fassinou ACR, Ayoub G, Lapinskas E, Pisano W, Jeang J, Stopka SA, Regan MS, Spetz J, Desai A, Lieberman F, Fisher JD, Pelton K, Huang RY, Nabors LB, Holdhoff M, Danda N, Strowd R, Desideri S, Walbert T, Ye X, Agar NYR, Grossman SA, Alexander BM, Wen PY, Ligon KL, Beroukhim R.
Surgical window of opportunity trial reveals mechanisms of response and resistance to navtemadlin (KRT-232) in patients with recurrent glioblastoma.
medRxiv [Preprint]. 2024 Aug 14:2024.08.12.24311893. doi: 10.1101/2024.08.12.24311893. PMID: 39211865. Interventional study. ˍ